据悉，本次拟购买资产为瑞盛生物55.00%股权，瑞盛生物是一家专注于口腔组织修复与再生材料的研发、生产和销售的高新技术企业，在用于种植牙的修复材料领域具备较强的市场竞争力;本次拟出售资产为药明海德30.00%的股权，药明海德控股股东为药明生物，主要从事人用疫苗(包括癌症治疗性疫苗)的CRDMO业务。shanghai hile bio-technology (603718.SH) released a major asset purchase and sale report (draft), for this transaction...
According to the Zhongtong finance and economics APP, shanghai hile bio-technology (603718.SH) released a major asset purchase and sale report (draft), in this transaction, the listed company intends to purchase 55% equity of Ruisheng biology from Melun management for $0.935 billion, and sell 30.00% equity of Ruisheng biology held by Wuxi bio to wuxi bio for $108.5 million.
The listed company intends to purchase 55.00% equity assets of Ruisheng biology from Melun management for $0.935 billion in cash; the listed company intends to sell 30.00% equity of Ruisheng biology held by Wuxi bio to Wuxi bio for $108.5 million.
It is reported that the intended purchase assets for this transaction is 55.00% equity of Ruisheng biology, which is a high-tech enterprise dedicated to the research, production, and sales of oral tissue repair and regeneration materials, with strong market competitiveness in the field of restorative materials for dental implants; the intended sale assets for this transaction is 30.00% equity of Ruisheng biology, Wuxi bio, with its controlling shareholder being Wuxi bio, mainly engaged in the CRDMO business of human vaccines (including cancer therapeutic vaccines).
With the growing trend of an aging society, the listed company is bullish on the growth space in the oral medical field, especially with the continuous penetration of the dental implant market, the market demand will continue to release and grow, and oral biological repair materials are expected to grow accordingly. After this transaction, the listed company will continue to focus on the biomedical field, further expand the main business of the listed company horizontally, deepen the "human protection" business layout, while disposing of relevant assets that are expected to be difficult to achieve the listed company's profit expectations and difficult to control operational decisions in the short term to obtain investment returns, focus on controllable resources, create more liquidity for the listed company, and strengthen the listed company's risk resistance.
